Fibrocell Science Inc

Fibrocell Science — Investor Presentation (April 2016)

22 slides from Fibrocell Science's investor presentation, Apr 18, 2016

  1. Slide 1: Corporate Presentation April 18, 2016

    Corporate Presentation April 18, 2016

  2. Slide 2: Forward-Looking Statements

    This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among ot

  3. Slide 3: Company Highlights

    Company Highlights • Cell and gene therapy company developing a pipeline of autologous biologics—based on a proprietary fibroblast platform—for localized treatment of diseases affecting the skin, connective tissue and joints • Phase II azficel-T program for Vocal Cord Scarring resulting in Chronic o

  4. Slide 4: Autologous Fibroblasts as a Platform for Therapy

    Autologous Fibroblasts as a Platform for Therapy • Fibroblasts repair tissue infrastructure by producing extracellular matrix proteins including collagen and growth factors •Most common cell in skin and connective tissue •Key advantages of our autologous fibroblast platform for creating cell and gen

  5. Slide 5: Two Product Engines – Multiple Therapeutics in Development

    Two Product Engines – Multiple Therapeutics in Development 5 Personalized Biologics Approach

  6. Slide 6: Development Pipeline

    Development Pipeline 6 Personalized Biologics Indication Research Pre-Clinical Development Phase I Phase II Phase III azficel-T* Vocal Cord Scarring Resulting in Chronic or Severe Dysphonia FCX-007√ Orphan Product Candidate Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013√ Linear Scleroderm

  7. Slide 7: Vocal Cord Scarring Resulting in Chronic or Severe Dysphonia

    Vocal Cord Scarring Resulting in Chronic or Severe Dysphonia 7 Disease Current Treatments Epidemiology Damage to the fibroblast layer causes scarring and edema, which limits air flow and results in severe and significant limitations in voice quality, often loss of voice Current treatments only addre

  8. Slide 8: Clinical Data Support Our Approach in Chronic Dysphonia

    Clinical Data Support Our Approach in Chronic Dysphonia Positive Phase I clinical trial results published in peer-reviewed journal2 • Injection of azficel-T into scarred vocal cord was well-tolerated in trial (n=5) All patients completed the trial No serious adverse events reported •Positive trend

  9. Slide 9: Chronic Dysphonia—Phase II Trial

    Chronic Dysphonia—Phase II Trial 9 • Fully enrolled 20+ subjects One dose per vocal cord per month x 3 treatments Last patient, last visit scheduled for 19 April 2016 •Double-blind, randomized, placebo-controlled • Four-month efficacy endpoint on three different scales: Voice Handicap Index (vali

  10. Slide 10: Recessive Dystrophic Epidermolysis Bullosa

    Recessive Dystrophic Epidermolysis Bullosa 10 Disease Current Treatments Epidemiology • Cause: A mutation in the COL7A1 gene that encodes for COL7 • Devastating, progressive, painful blistering disease that often leads to death • Diagnosed at infancy • High mortality rate • Current treatments only a

  11. Slide 11: FCX-007 Providing Hope for RDEB Patients

    FCX-007 Providing Hope for RDEB Patients 11 RDEB patients do not produce type VII collagen (COL7) due to mutation in COL7A1 gene Main component of anchoring fibrils that connect skin layers FCX-007 is an autologous human dermal fibroblast transduced with a lentiviral (LV) vector encoded for COL7A1

  12. Slide 12: Detection of COL7 Expression by Immunofluorescence

    12 Detection of COL7 Expression by Immunofluorescence • COL7 expression noted from FCX-007 replicates (red) • FCX-007 expresses higher levels of COL7 than normal human dermal fibroblasts (NHDF) as depicted by a brighter signal • No expression in RDEB-positive cells NHDF RDEB+ FCX-007-1 FCX-007-2 Mag

  13. Slide 13: COL7 Expression Confirmation

    COL7 Expression Confirmation 13 Culture supernatant evaluated for COL7 expression • ELISA assay indicates virus dose-dependent protein expression • Trimeric form of COL7 produced by RDEB patient fibroblasts transduced with LV-COL7 •Must be trimeric to be functional Reference: Bruckner-Tuderman, Leen

  14. Slide 14: FCX-007 In Vitro Results Summary

    FCX-007 In Vitro Results Summary 14 Results Suggest* Ability to successfully make the vector Ability for full-scale FCX-007 production Full gene integration into cell genome COL7 is being produced from FCX-007 COL7 produced from FCX-007 is the correct size and structure COL7 produced from FCX-007 is

  15. Slide 15: FCX-007 Phase I/II Clinical Trial Design

    FCX-007 Phase I/II Clinical Trial Design 15 Title A Phase I/II Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Statement of Purpose The purpose of this study is threefold: 1) To evaluate the safety of FCX-007 2) To eva

  16. Slide 16: Linear Scleroderma

    Linear Scleroderma 16 Disease Epidemiology • Excess production of extracellular matrix characterized by skin fibrosis and linear scars • The linear areas of skin thickening may extend to underlying tissue and muscle in children which may impair growth in affected legs and arms or forehead • Lesions

  17. Slide 17: FCX-013 Development Progressing

    FCX-013 Development Progressing 17 •Product profile Autologous fibroblasts genetically modified using lentivirus  Incorporates Intrexon’s RheoSwitch Therapeutic System® (RTS®) to enhance safety • RTS switch allows regulation of protein expression •Preparing scale-up manufacturing •Demonstrated pro

  18. Slide 18: FCX-013 Proof-of-Concept Study

    FCX-013 Proof-of-Concept Study 18 • Study Design  Bleomycin treated SCID mouse model  N=30 mice over test and control groups  Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence of FCX-013 and oral ligand • Result  Bleomycin treatment resulted in skin

  19. Slide 19: New Gene Therapy Collaboration with Intrexon

    New Gene Therapy Collaboration with Intrexon 19 •Goal is to deliver a protein therapy locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy •Collaboration combines Fibrocell’s autologous fibroblast technology with Intrexon’s cell

  20. Slide 20: Expected Milestones & Corporate Information

    Expected Milestones & Corporate Information 20 •Cash = $13.1 million at 31 Mar 2016 (preliminary, unaudited) •43.9 million common shares of FCSC outstanding at 31 Mar 2016  5.3 million warrants; 4.0 million options Expected Milestones Timing FCX-007 Phase I/II Trial Initiation 2Q16 azficel-T Phase

  21. Slide 21: Company Highlights

    Company Highlights • Cell and gene therapy company developing a pipeline of autologous biologics—based on a proprietary fibroblast platform—for localized treatment of diseases affecting the skin, connective tissue and joints • Phase II azficel-T program for Vocal Cord Scarring resulting in Chronic o

  22. Slide 22: References

    References 1Data on file. Fibrocell Science, Inc. 2Chhetri, Dinesh. Injection of Cultured Autologous Fibroblasts for Human Vocal Fold Scars. The Laryngoscope 121(4):785-792, 2011. 3 The Dystrophic Epidermolysis Research Association of America (DebRA). DEB brochure, page 6: http://www.debra.org/pdfs/

Fibrocell Science — Investor Presentation (April 2016) on 6ix